Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Dolastatin-10. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 6/20 | 0.32 |
| ▸ | CTSE | P14091 | 6/20 | 0.32 |
| ▸ | BACE1 | P56817 | 4/20 | 0.32 |
| ▸ | REN | P00797 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolastatin-10 SCHEMBL18793204 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL13135112 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL12016480 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL5286 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL16730776 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL13378458 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL23387006 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL22126284 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL22126283 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL14583139 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1442 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743124-A1 | DE-N-ACETYLATED POLYSIALIC ACID (DPSA) BINDING AGENT, CONJUGATES, AND METHOD OF USING SAME | Saccharo, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122055170-A | Des-N-acetylated polysialic acid (dPSA) binders, conjugates, and methods of use thereof | 萨克罗有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-3766510-B1 | CONJUGATES AND PRODRUGS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CENTRE NAT RECH SCIENT (FR) | 2026-05-13 | — | — | EP | claimed |
| EP-3624854-B1 | PROTEIN-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCERS | UNIV STRASBOURG (FR) | 2026-04-15 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4448107-B1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | FACULDADE DE FARMACIA DA UNIV DE LISBOA (PT) | 2025-11-05 | — | — | EP | claimed |
| US-12398172-B2 | Therapeutic oligonucleotides | CARIS SCIENCE, INC. (US) | 2025-08-26 | — | — | US | claimed |
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | claimed |
| EP-4186529-B1 | IMPROVED ANTIBODY-PAYLOAD CONJUGATES (APCS) PREPARED BY SITE-SPECIFIC CONJUGATION UTILIZING GENETIC CODE EXPANSION | VERAXA BIOTECH GMBH (DE) | 2025-07-09 | — | — | EP | claimed |
| WO-2022150517-A1 | MODULATION OF CD46 CELL SURFACE EXPRESSION AND THERAPEUTIC USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022150512-A1 | MODULATION OF CD46 CELL SURFACE MARKER IN BOTH ANDROGEN RECEPTOR-POSITIVE AND NEGATIVE CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022098972-A1 | COMBINATION-THERAPY ANTIBODY DRUG CONJUGATE WITH IMMUNE CELL INHIBITOR | SEAGEN INC. (US) | 2022-05-12 | — | — | WO | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| EP-3546448-B1 | DI-SUBSTITUTED MALEIC AMIDE LINKER FOR ANTIBODY-DRUG CONJUGATING AND PREPARATION METHOD AND USE THEREOF | MABWELL SHANGHAI BIOSCIENCE CO LTD (CN) | 2022-04-06 | — | — | EP | claimed |
| US-20220089763-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | GENZYME CORPORATION | 2022-03-24 | — | — | US | claimed |
| WO-2022056318-A1 | ANTIBODIES CONTAINING UNNATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | BRICKBIO, INC. (US) | 2022-03-17 | — | — | WO | claimed |
| WO-2022032020-A1 | IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF | FORTIS THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | claimed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | SSTR2 3350/4885CYP3A4 3207/4885FOLH1 9/4885 |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | RNASE1, GUSB, DPEP1 | SSTR2 4472/4885CYP3A4 411/4885FOLH1 27/4885 |
| US-20220089763-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | CD2BP2, SIGLEC7, B3GAT3 | SSTR2 3787/4885CYP3A4 3892/4885FOLH1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.